Astria Therapeutics Inc
ATXS12.510USD
+0.080+0.64%
Fechamento 11/07, 16:00（ET）Cotações atrasadas em 15 min
705.99MValor de mercado
PerdaP/L TTM
Mais detalhes de Astria Therapeutics Inc Empresa
Astria Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for allergic and immunological diseases. The Company's lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Its second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis (AD). The Company owns two patent families directed to STAR-0215. The first patent family is directed to the composition of matter of its product candidate STAR-0215 and its use in treating various plasma kallikrein associated disorders including HAE. In the second patent family, the Company owns one International (PCT) patent application directed to methods of treating various plasma-kallikrein associated disorders, including HAE, with specific dosing regimens of the STAR-0215 antibody.
Informações de Astria Therapeutics Inc
Código da empresaATXS
Nome da EmpresaAstria Therapeutics Inc
Data de listagemJun 25, 2015
CEODr. Jill C. Milne, Ph.D.
Número de funcionários78
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 25
Endereço22 Boston Wharf Road
CidadeBOSTON
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal02210
Telefone16173491971
Sitehttps://astriatx.com/
Código da empresaATXS
Data de listagemJun 25, 2015
CEODr. Jill C. Milne, Ph.D.
Executivos da empresa Astria Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Jonathan Violin, Ph.D.
Dr. Jonathan Violin, Ph.D.
Independent Director
Independent Director
263.32K
--
Mr. Noah Clauser
Mr. Noah Clauser
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Elizabeth Higgins
Ms. Elizabeth Higgins
Investor Relations
Investor Relations
--
--
Dr. Joanne T. Beck, Ph.D.
Dr. Joanne T. Beck, Ph.D.
Independent Director
Independent Director
--
--
Dr. Jill C. Milne, Ph.D.
Dr. Jill C. Milne, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
--
--
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Director
Independent Director
--
--
Mr. Andrew Komjathy
Mr. Andrew Komjathy
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Sunil Agarwal, M.D.
Dr. Sunil Agarwal, M.D.
Independent Director
Independent Director
--
--
Mr. Benjamin Scott Harshbarger
Mr. Benjamin Scott Harshbarger
Chief Legal Officer
Chief Legal Officer
--
--
Ms. Andrea Matthews
Ms. Andrea Matthews
Chief Business Officer
Chief Business Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Jonathan Violin, Ph.D.
Dr. Jonathan Violin, Ph.D.
Independent Director
Independent Director
263.32K
--
Mr. Noah Clauser
Mr. Noah Clauser
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Elizabeth Higgins
Ms. Elizabeth Higgins
Investor Relations
Investor Relations
--
--
Dr. Joanne T. Beck, Ph.D.
Dr. Joanne T. Beck, Ph.D.
Independent Director
Independent Director
--
--
Dr. Jill C. Milne, Ph.D.
Dr. Jill C. Milne, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
--
--
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Director
Independent Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: dom, 26 de out
Atualizado em: dom, 26 de out
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Perceptive Advisors LLC
11.49%
Vestal Point Capital, LP
8.01%
Forbion Capital Partners
7.28%
Fidelity Management & Research Company LLC
6.48%
Magnetar Capital Partners LP
5.87%
Outro
60.87%
Investidores
Investidores
Proporção
Perceptive Advisors LLC
11.49%
Vestal Point Capital, LP
8.01%
Forbion Capital Partners
7.28%
Fidelity Management & Research Company LLC
6.48%
Magnetar Capital Partners LP
5.87%
Outro
60.87%
Tipos de investidores
Investidores
Proporção
Investment Advisor
31.18%
Investment Advisor/Hedge Fund
22.93%
Venture Capital
15.69%
Private Equity
11.49%
Hedge Fund
11.30%
Research Firm
4.23%
Individual Investor
0.49%
Pension Fund
0.17%
Bank and Trust
0.09%
Outro
2.43%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
263
57.85M
102.50%
-13.18M
2025Q2
263
60.10M
106.50%
-10.94M
2025Q1
281
59.08M
104.77%
-12.46M
2024Q4
268
59.35M
105.17%
-9.44M
2024Q3
247
57.14M
101.27%
-10.09M
2024Q2
228
56.25M
102.41%
-8.30M
2024Q1
210
58.30M
106.65%
+7.30M
2023Q4
179
37.20M
102.69%
+9.26M
2023Q3
171
23.97M
88.11%
-4.33M
2023Q2
175
25.83M
94.82%
-888.95K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Perceptive Advisors LLC
6.49M
11.49%
--
--
Jun 30, 2025
Vestal Point Capital, LP
4.52M
8.01%
+342.00K
+8.18%
Jun 30, 2025
Forbion Capital Partners
4.11M
7.28%
+285.00K
+7.46%
Jun 30, 2025
Fidelity Management & Research Company LLC
3.66M
6.48%
-1.15M
-23.93%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.18M
5.64%
-222.43K
-6.53%
Jun 30, 2025
Fidelity Institutional Asset Management
2.80M
4.97%
+671.87K
+31.52%
Jun 30, 2025
TCG Crossover Management, LLC
2.76M
4.89%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
2.52M
4.47%
-116.58K
-4.41%
Jun 30, 2025
VR Adviser, LLC
2.46M
4.35%
--
--
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: qui, 6 de nov
Atualizado em: qui, 6 de nov
Nome
Proporção
Virtus LifeSci Biotech Clinical Trials ETF
0.94%
ALPS Medical Breakthroughs ETF
0.24%
AltShares Merger Arbitrage ETF
0.09%
iShares Micro-Cap ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco Nasdaq Biotechnology ETF
0.04%
iShares Biotechnology ETF
0.03%
Avantis US Small Cap Equity ETF
0.03%
iShares Russell 2000 Value ETF
0.02%
iShares Russell 2000 ETF
0.01%
Ver Mais
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.94%
ALPS Medical Breakthroughs ETF
Proporção0.24%
AltShares Merger Arbitrage ETF
Proporção0.09%
iShares Micro-Cap ETF
Proporção0.05%
ProShares Ultra Nasdaq Biotechnology
Proporção0.04%
Invesco Nasdaq Biotechnology ETF
Proporção0.04%
iShares Biotechnology ETF
Proporção0.03%
Avantis US Small Cap Equity ETF
Proporção0.03%
iShares Russell 2000 Value ETF
Proporção0.02%
iShares Russell 2000 ETF
Proporção0.01%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Aug 19, 2021
Merger
6→1
Aug 19, 2021
Merger
6→1
Aug 19, 2021
Merger
6→1
Aug 19, 2021
Merger
6→1
Data
Tipo
Proporção
Aug 19, 2021
Merger
6→1
Aug 19, 2021
Merger
6→1
Aug 19, 2021
Merger
6→1
Aug 19, 2021
Merger
6→1
